Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

12 Dec 25

Updated

01 Jul 26

Views

Not Invested

Shared on 01 Jul 26

Fair value Decreased 14%

CRMD: Future Anti Infective Portfolio Expansion Will Drive Re Rating Potential

CorMedix’s antifungal drug posts encouraging late-stage trial results, setting up the next step with regulators and raising the stakes for a broader infection-fighting lineup beyond its lead product. At the same time, the company flags a coming reimbursement change that could make revenue bumpier, even as the market resets its expectations.

13 views

Fair Value vs Share Price

US$19

vs US$8.2356.7% undervalued

-2.9%

Revenue growth

13.2%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on CorMedix

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Very undervalued with solid track record.

Market capUS$664.1m

PB1.4x

Estimated Growth4.1%

Dividend YieldN/A

Full analysis

CEO & management

Joseph Todisco

CEO

2.6yrs

CEO Tenure

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.